Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes.

Brendon L Neuen Clare ArnottVlado PerkovicGemma FigtreeDick de ZeeuwGreg FulcherMin JunMeg J JardineSophia ZoungasCarol PollockKenneth W MahaffeyBruce C Neal Hiddo J Lambers Heerspink

Published in: Diabetes, obesity & metabolism (2020)

Treatment with SGLT2 inhibitors results in clear and consistent reductions in cardiovascular, kidney and mortality outcomes regardless of whether patients are receiving or not receiving metformin.

Keyphrases

end stage renal disease
cardiovascular events
newly diagnosed
ejection fraction
risk factors
prognostic factors
peritoneal dialysis
cardiovascular disease
metabolic syndrome
adipose tissue
skeletal muscle
patient reported outcomes
patient reported
combination therapy